Our Strategy
We are a fast-growing clinical-stage biopharmaceutical company developing a portfolio of therapeutic candidates for metabolic disease. Our goal is to develop first-in-class and best-in-class single-agent and combination treatments to benefit patients with obesity, type 2 diabetes, and non-alcoholic steatohepatitis (NASH).
Our Programs
The main building blocks of our portfolio are incretin receptor agonists - including both peptide and small molecule agonists for GLP-1 and GIP receptors. Incretins have broad-acting mechanisms with numerous beneficial effects on metabolism and liver health. We are developing these molecules as single-agent and combination therapies for various chronic metabolic conditions.
